Webinar – NGS for HLA, a Better Way to Genotype

11/09/2014

Are you interested in Next Generation HLA Typing? Watch this latest webinar presentation on Holotype HLA™ – HLA Genotyping Assay and Software for NGS data. Date: Thursday, 18th of September, 2014 Time: 12:00–1pm EST / 18:00–19:00 pm CEST A live Q&A session will follow the presentation, offering you the opportunity...

Omixon at This Year’s BSHI Conference

10/09/2014

Arnold Feher and Tim Hague attended the BSHI conference in Manchester. There was a very interesting series of talks about the state of transplantation in the UK, plus a trade show, poster exhibition and some lunchtime presentations from the corporate sponsors concentrating on the use of NGS for HLA....

Cancer Biomarkers

21/08/2014

When tackling any disease, the first step is to learn what signals its presence and what else these signs can mean. In discussing cancer, these signs are referred to as cancer biomarkers. Some organisations define a biomarker as a molecule that the cancerous tumor has secreted into the body,...

Omixon Launches Holotype HLA™ for NGS-based HLA Genotyping

18/07/2014

Omixon announces the launch of Omixon Holotype HLA™ – a combination Assay and Software product that leverages the power of Next Generation Sequencing (NGS), for use on the Illumina® MiSeq sequencing platform. The assay and software have been optimized through cohesive collaboration with the Monos lab at The Children’s...

Omixon Celebrates a Successful EFI 2014

03/07/2014

Omixon took a team of 8 to the 28th EFI (European Histocompatibility and Immunogenetics) Conference, held in Stockholm. Omixon’s “A Team” of defenders (science nerds), midfielders (marketing bods) and strikers (sales weenies) were superbly captained by the indefatigable Craig Funnell (Director of Sales and Marketing), and brought super-sub Attila...